p38 Kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas
摘要:
Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range. (C) 2000 Elsevier Science Ltd. All rights reserved.
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
[EN] INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS<br/>[FR] INHIBITION DE L'ACTIVITE DE LA p38 KINASE PAR DES ARYL-UREES
申请人:BAYER CORPORATION
公开号:WO1998052558A1
公开(公告)日:1998-11-26
(EN) This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.(FR) Cette invention se rapporte à un groupe d'aryl-urées utilisées pour traiter des troubles liés à la production de cytokines, autres que le cancer et les maladies liées à la présence d'enzymes protéolytiques autres que le cancer, ainsi qu'à des compositions pharmaceutiques destinées à ce type de thérapie.
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.